Market Place
Sourcing Support
Nxera Pharma Enrolls 1st Insomnia Patient in Ph 3 Trial
04 Dec 2024 //
GLOBENEWSWIRE
Nxera Pharma`s QUVIVIQ Approved In Japan For Insomnia
23 Sep 2024 //
GLOBENEWSWIRE
New data with daridorexant to be presented at SLEEP 2024
03 Jun 2024 //
GLOBENEWSWIRE
Sosei Announces Submission of New Drug Application in Japan for Daridorexant
31 Oct 2023 //
GLOBENEWSWIRE
Idorsia announces its insomnia medication, QUVIVIQ, is now covered by CVS
10 Jul 2023 //
PR NEWSWIRE
Idorsia launches QUVIVIQ (daridorexant) in Switzerland
12 Jun 2023 //
GLOBENEWSWIRE
Idorsia notes potential $440.8M Asia licensing deal to extend cash runway
06 Jun 2023 //
ENDPTS
Idorsia Announces Support for a Trial being Conducted by the U.S. Dept QUVIVIQ
10 May 2023 //
PR NEWSWIRE
Idorsia`s insomnia drug enters clinic as a treatment for PTSD
10 May 2023 //
FIERCE PHARMA
Health Canada approves QUVIVIQ forthe management of adult patients with insomnia
03 May 2023 //
GLOBENEWSWIRE
Idorsia requests to de-schedule DORA insomnia drugs
08 Apr 2023 //
FIERCE PHARMA
2022 drug approvals: Biopharma delivered 37 new drugs
03 Jan 2023 //
FIERCE PHARMA
Roche: Changes in the Board of Directors and the Corporate Executive Committee
12 Dec 2022 //
GLOBENEWSWIRE
Long-term safety & tolerability results daridorexant patients insomnia disorder
12 Dec 2022 //
GLOBENEWSWIRE
Swissmedic approves QUVIVIQ – a first-in-class treatment for CID
05 Dec 2022 //
GLOBENEWSWIRE
Idorsia sleep survey will keep you up at night
01 Dec 2022 //
FIERCEPHARMA
QUVIVIQ (daridorexant) – Europe’s first dual orexin receptor antagonist
14 Nov 2022 //
GLOBENEWSWIRE
Idorsia`s Quviviq (daridorexant) Receives Approval in the Europe
11 Nov 2022 //
EMA
Idorsia Japan announces positive results with daridorexant in a Phase 3 study
03 Oct 2022 //
GLOBENEWSWIRE
Idorsia Pharma Generic Quviviq (daridorexant) Receives Approval in Europe
08 Jun 2022 //
EMA
Idorsia U.S. Announces First Wave of Patients Prescribed QUVIVIQ
13 May 2022 //
PRNEWSWIRE
Idorsia`s new treatment QUVIVIQ is now available in the US for insomnia
02 May 2022 //
PRNEWSWIRE
CHMP recommends Idorsia’s dual acting treatment Quviviq for insomnia patients
28 Feb 2022 //
PHARMATIMES
QUVIVIQ (daridorexant) recommended for approval in Europe
24 Feb 2022 //
GLOBENEWSWIRE
Idorsia expands commercialization partnership with Syneos Health
26 Jan 2022 //
GLOBENEWSWIRE
The Lancet Neurology reports impact of daridorexant on insomnia
20 Jan 2022 //
GLOBENEWSWIRE
Idorsia wins its first FDA approval with insomnia drug Quviviq
11 Jan 2022 //
ENDPTS
FDA accepts the new drug application for review of Idorsia’s daridorexant
09 Mar 2021 //
GLOBENEWSWIRE
Idorsia submits investigational insomnia treatment daridorexant to the EMA
03 Mar 2021 //
PHARMATIMES
Idorsia submits investigational insomnia treatment daridorexant to the EMA
02 Mar 2021 //
PHARMATIMES
Idorsia announces capital increase to prepare for launch of daridorexant & fund
13 Oct 2020 //
GLOBENEWSWIRE
Daridorexant Phase 3 results in insomnia presented at SLEEP 2020
28 Aug 2020 //
GLOBENEWSWIRE
Daridorexant Ph3 results in insomnia to be presented at SLEEP 2020
13 Aug 2020 //
GLOBENEWSWIRE
Idorsia Japan confirms daridorexant dose response in Japanese patients
06 Aug 2020 //
GLOBENEWSWIRE
